Clinical Trial Update: A Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of Ivacaftor in Subjects With Cystic Fibrosis Who Are Less Than 24 Months of Age and Have an Ivacaftor-Responsive CFTR Mutation [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating safety, pharmacokinetics, and pharmacodynamics of ivacaftor in cystic fibrosis patients under 24 months with Ivacaftor-responsive CFTR …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cystic Fibrosis

Drugs mentioned

• Ivacaftor (ivacaftor)

Snippet

Sponsor: Vertex Pharmaceuticals Incorporated | Conditions: Cystic Fibrosis | Phase 3 | Status: COMPLETED | Results posted: 2023-09-07